Another research asserts that the lncRNA MALAT1/miR-328 axis promotes imatinib resistance and cell proliferation, opening up new research directions for MALAT1 as a possible therapeutic target in CML [41]. This evidence concerns the gene MALAT1 and chronic myelogenous leukemia, BCR-ABL1 positive.